The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F24%3A00079601" target="_blank" >RIV/65269705:_____/24:00079601 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/24:00135939 RIV/00098892:_____/24:10158634 RIV/00843989:_____/24:E0110960 RIV/00064190:_____/24:10001210
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0300289623004039?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.arbres.2023.12.002" target="_blank" >10.1016/j.arbres.2023.12.002</a>
Alternative languages
Result language
angličtina
Original language name
The Impact of Switching to a Second Antifibrotic in Patients With Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study From the EMPIRE Registry
Original language description
<bold>Introduction: </bold>Most patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotics (AF) have progressive disease despite treatment. A switch of AF may improve survival, but evidence from randomised controlled trials is missing. We aimed to evaluate the efficacy of an AF switch on survival and FVC decline in patients from the European MultiPartner IPF registry (EMPIRE). <bold>Methods: </bold>The study included 612 patients who discontinued the first antifibrotic therapy. Patients were grouped and analysed from two perspectives: (1) whether they had received a second antifibrotic treatment after the discontinuation of the first therapy, and (2) a reason for discontinuation of the first AF - "lack of efficacy" (LE) and "intolerance" (INT). <bold>Results: </bold>While 263 (43%) of 612 patients received no second AF ("non-switched"), 349 (57%) patients switched. Overall survival was higher in patients who received a second AF (median 50 vs. 29 months; adjusted HR 0.64, P=0.023). Similarly, the annual FVC decline was significantly reduced in switched patients: -98ml/y in switched and -172ml/y in non-switched patients (P=0.023), respectively. The switched patients had similar risk for mortality in both LE and INT groups (adjusted HR 0.95, P=0.85). The high impact of switching on survival was demonstrated in LE patients (adjusted HR 0.27, P<0.001). <bold>Conclusion: </bold>The patients without a second AF had significantly shorter overall survival. Our analysis suggests the importance of switching patients with an ineffective first AF therapy to a second AF therapy.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Archivos de Bronconeumologia
ISSN
0300-2896
e-ISSN
1579-2129
Volume of the periodical
60
Issue of the periodical within the volume
2
Country of publishing house
ES - SPAIN
Number of pages
8
Pages from-to
80-87
UT code for WoS article
001170483700001
EID of the result in the Scopus database
2-s2.0-85181946229